The global mRNA manufacturing and mRNA synthesis market is estimated to reach USD 1.95 billion in 2023 and is anticipated to decline at a CAGR of -1.7% during the forecast period 2022-2035.

Over the next decade, market projections indicate a decline in the market size due to an expected decrease in demand for COVID vaccines until 2035. However, the emergence of messenger ribonucleic acid (mRNA) as a pivotal therapeutic method in modern healthcare is noteworthy. Since the onset of the COVID-19 pandemic, mRNA therapeutics and vaccine production have gained significant attention, presenting a groundbreaking approach to combat not only COVID-19 but also a range of other conditions such as oncological, infectious, and genetic disorders. Currently, there are more than 195 mRNA therapeutics and vaccines in different developmental stages or already available for various medical conditions.

This surge in mRNA-based treatments has led to a noticeable increase in the demand for mRNA production capabilities. The manufacturing of mRNA therapeutics and vaccines is complex and requires significant capital investment, along with specialized expertise. Consequently, developers of mRNA-based therapies and vaccines are actively exploring strategies to overcome existing challenges. One promising avenue among the available options is the outsourcing of production to mRNA Contract Development and Manufacturing Organizations (CDMOs).

Looking forward, as a greater number of RNA-based candidates progress through clinical phases and enter the market, we anticipate substantial growth in the mRNA synthesis and manufacturing market during the forecast period.


Report Coverage
? An executive summary of the key insights captured during research. It offers a high-level view on the current state of the mRNA synthesis and contract manufacturing services market and its likely evolution in the short to mid-term and long term.
? Overview of mRNA, highlighting details on its structure and the historical evolution of mRNA vaccines. It also presents information on the in-vitro synthesis of mRNA, its applications in various therapeutic modalities and the challenges associated with the process. Additionally, it features a discussion on the commonly outsourced manufacturing operations and their advantages. .
? Detailed assessment of the overall market landscape of the companies offering mRNA custom synthesis services, based on several relevant parameters, such as year of establishment, company size, location of headquarters, type of service(s) offered, input for synthesis, type of purification method(s), scale of operation and GMP compliance.
? A detailed competitiveness analysis of mRNA custom synthesis service providers based on supplier strength and service strength
? A comprehensive assessment of the overall market landscape of mRNA contract manufacturing service providers, based on several relevant parameters, including year of establishment, company size, location of headquarters, location of manufacturing facilities, type of product(s) manufactured, type of service(s) offered and scale of operation.
? An in-depth company competitiveness analysis of mRNA contract manufacturing service providers based in North America, Europe and Asia-Pacific. The analysis compares the contract service providers on the basis of various parameters, such as their supply strength and service portfolio strength.
? A detailed overview of the current market landscape of companies engaged in the development of mRNA synthesis kits, based on several relevant parameters, such as type of enzyme, kit components, type of enzyme mix used, mRNA component modified, yield per reaction, number of reactions, reaction run time and kit price.
? A product competitiveness analysis of the mRNA synthesis kits, based on supplier power and product competitiveness
? Detailed profiles of the key players offering services for the synthesis and manufacturing of mRNA. and key mRNA synthesis kit providers. Each profile includes a brief overview of the company, along with information on the mRNA synthesis kits portfolio.
? A detailed analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, target patient population, therapeutic area, type of sponsor / collaborator, leading industry players, and regional distribution of trials.
? An analysis of recent partnerships inked between stakeholders engaged in this domain, since 2014, covering acquisitions, manufacturing agreements, fill / finish service agreements, supply agreements, service alliance, and other relevant deals.
? A comprehensive analysis of over 35 mRNA-based therapeutics / vaccines developers that are likely to partner with mRNA contract manufacturing service providers.
? A comprehensive market forecast analysis, highlighting the future potential of the market till 2035. We have segregated the current and upcoming opportunity based on type of product (drug substances (APIs) and drug products (FDFs)), application areas (mRNA-based vaccines and mRNA-based therapeutics), therapeutic areas (infectious diseases, oncological disorders and other diseases), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).

Key Market Companies
? Aldevron
? APExBIO
? Biomay
? BioNTech
? CELLSCRIPT
? CureVac
? biosynthesis
? eTheRNA, Eurogentec
? Jena Biosciences
? Moderna
? New England Biolabs
? Thermo Fisher Scientific
? TriLink BioTechnologies